The Research Models and Services (RMS) segment focuses on providing researchers with the foundational tools necessary for drug discovery and preclinical development. This includes the production and sale of rodent research model strains, specifically purpose-bred rats and mice. The segment also offers genetically engineered models and services (GEMS), insourcing solutions, and research animal diagnostic services. R&D activities within RMS are geared towards developing new and improved research models that better mimic human diseases, enhancing the predictive power of preclinical studies. Technologies used include advanced breeding techniques, genetic engineering, and diagnostic assays. This segment directly impacts patient outcomes by ensuring the reliability and translatability of preclinical research, ultimately accelerating the development of effective therapies. Future opportunities lie in expanding the range of available models and services to meet the evolving needs of the biopharmaceutical industry. The RMS segment holds a strong market position due to its extensive portfolio and expertise in research model development.

The Discovery and Safety Assessment (DSA) segment provides comprehensive services to identify and validate novel drug targets, chemical compounds, and antibodies. This includes early and in vivo discovery services, culminating in non-clinical drug and therapeutic candidates ready for safety assessment. Safety assessment services encompass toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics. R&D efforts in DSA are focused on developing innovative assays and methodologies to improve the accuracy and efficiency of drug safety evaluations. Technologies employed include advanced imaging techniques, high-throughput screening, and sophisticated bioanalytical platforms. The DSA segment plays a crucial role in ensuring the safety and efficacy of new therapies, directly impacting patient safety and regulatory approval processes. Future growth potential lies in expanding capabilities in areas such as immunotoxicology and predictive toxicology. The segment's competitive advantage stems from its integrated service offerings and expertise in both discovery and safety assessment.

The Manufacturing segment provides quality control testing for sterile and non-sterile pharmaceuticals and consumer products, utilizing both conventional and rapid in vitro methods. It also offers specialized testing of biologics outsourced by pharmaceutical and biotechnology companies, as well as avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used in vaccine manufacturing. R&D activities in this segment focus on developing and validating new testing methodologies to ensure product quality and safety. Technologies used include advanced microbiological assays, molecular diagnostics, and cell-based assays. This segment contributes to patient safety by ensuring the quality and sterility of pharmaceutical products and the reliability of vaccine manufacturing. Future opportunities include expanding services in cell and gene therapy testing and developing innovative rapid testing methods. The segment's market position is strengthened by its specialized expertise in biologics testing and avian vaccine services.